SBHMY (Sino Biopharmaceutical) Long-Term Debt : $139 Mil (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Long-Term Debt?

Sino Biopharmaceutical's Long-Term Debt for the quarter that ended in Jun. 2024 was $139 Mil.

Sino Biopharmaceutical's quarterly Long-Term Debt increased from Jun. 2023 ($98 Mil) to Dec. 2023 ($150 Mil) but then declined from Dec. 2023 ($150 Mil) to Jun. 2024 ($139 Mil).

Sino Biopharmaceutical's annual Long-Term Debt declined from Dec. 2021 ($818 Mil) to Dec. 2022 ($564 Mil) and declined from Dec. 2022 ($564 Mil) to Dec. 2023 ($150 Mil).

Sino Biopharmaceutical Long-Term Debt Historical Data

The historical data trend for Sino Biopharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Long-Term Debt Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

1,124.20

1,890.64

818.38

564.26

150.48

Sino Biopharmaceutical Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial															1,126.58	564.26	98.04	150.48	139.22

Sino Biopharmaceutical (OTCPK:SBHMY) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sino Biopharmaceutical Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.